WO2013179143A3 - Sensitization of cancer cells by the removal of soluble tumor necrosis factor receptors - Google Patents

Sensitization of cancer cells by the removal of soluble tumor necrosis factor receptors Download PDF

Info

Publication number
WO2013179143A3
WO2013179143A3 PCT/IB2013/001583 IB2013001583W WO2013179143A3 WO 2013179143 A3 WO2013179143 A3 WO 2013179143A3 IB 2013001583 W IB2013001583 W IB 2013001583W WO 2013179143 A3 WO2013179143 A3 WO 2013179143A3
Authority
WO
WIPO (PCT)
Prior art keywords
patient
necrosis factor
sensitization
removal
tumor necrosis
Prior art date
Application number
PCT/IB2013/001583
Other languages
French (fr)
Other versions
WO2013179143A2 (en
Inventor
Sabine Berg
Peter Wiesner
Original Assignee
Biopheresis Technologies, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/002340 external-priority patent/WO2012163544A1/en
Application filed by Biopheresis Technologies, Inc. filed Critical Biopheresis Technologies, Inc.
Publication of WO2013179143A2 publication Critical patent/WO2013179143A2/en
Publication of WO2013179143A3 publication Critical patent/WO2013179143A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
    • A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
    • A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The present invention relates to a molecule binding to soluble tumor necrosis factor receptor (sTNFR) for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent, wherein said molecule is immobilized on a solid support that is contacted with a body fluid of said patient. Furthermore, the present invention refers to a method for sensitizing a tumor cell and to a body fluid from which sTNFR has been removed for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent. Moreover, the present invention refers to a chemotherapeutic agent for use in a method for treating a tumor in a patient for sensitizing a tumor cell of said tumor in said patient to a treatment with said chemotherapeutic agent.
PCT/IB2013/001583 2012-06-01 2013-05-31 Sensitization of cancer cells by the removal of soluble tumor necrosis factor receptors WO2013179143A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2012/002340 WO2012163544A1 (en) 2011-06-01 2012-06-01 Removal of soluble tumor necrosis factor receptor 2 (stnfr2)
EPPCT/EP2012/002340 2012-06-01
EP12196527 2012-12-11
EP12196527.1 2012-12-11

Publications (2)

Publication Number Publication Date
WO2013179143A2 WO2013179143A2 (en) 2013-12-05
WO2013179143A3 true WO2013179143A3 (en) 2014-05-01

Family

ID=47500945

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/001583 WO2013179143A2 (en) 2012-06-01 2013-05-31 Sensitization of cancer cells by the removal of soluble tumor necrosis factor receptors

Country Status (1)

Country Link
WO (1) WO2013179143A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115957347A (en) 2014-10-03 2023-04-14 纳米提克斯有限责任公司 Compositions and methods for inhibiting biological activity of soluble biomolecules
EA201890391A1 (en) 2015-07-29 2018-08-31 НАНОТИКС, ЭлЭлСи MODULAR COMPOSITIONS FOR UTILIZATION OF SOLUBLE BIOMOLECULES AND RELATED METHODS
IL299915A (en) 2017-01-04 2023-03-01 Nanotics Llc Methods for assembling scavenging particles
US11345725B2 (en) 2019-09-16 2022-05-31 Research Foundation Of The City University Of New York Bis-thioether stapled peptides as inhibitors of PRC2 function
WO2022166720A1 (en) * 2021-02-05 2022-08-11 华南理工大学 Serum albumin-based fusion protein, and nano-assembly, preparation method therefor and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061085A2 (en) * 1998-05-22 1999-12-02 Lentz M Rigdon Method and compositions for treatment of cancers
WO2001037873A2 (en) * 1999-11-10 2001-05-31 Lentz M Rigdon Method and system to remove cytokine inhibitor in patients
WO2005107802A2 (en) * 2004-04-30 2005-11-17 Biopheresis Technologies, Llc Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
WO2012163544A1 (en) * 2011-06-01 2012-12-06 Biopheresis Technologies, Inc. Removal of soluble tumor necrosis factor receptor 2 (stnfr2)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4708713A (en) 1984-11-16 1987-11-24 Anisa Medical, Inc. Method and system for removing immunosuppressive components from the blood of mammals

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061085A2 (en) * 1998-05-22 1999-12-02 Lentz M Rigdon Method and compositions for treatment of cancers
WO2001037873A2 (en) * 1999-11-10 2001-05-31 Lentz M Rigdon Method and system to remove cytokine inhibitor in patients
WO2005107802A2 (en) * 2004-04-30 2005-11-17 Biopheresis Technologies, Llc Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
WO2012163544A1 (en) * 2011-06-01 2012-12-06 Biopheresis Technologies, Inc. Removal of soluble tumor necrosis factor receptor 2 (stnfr2)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MEREDITH LENTZ ET AL: "Reduction of Plasma Levels of Soluble Tumor Necrosis Factor and Interleukin-2 Receptors by Means of a Novel Immunoadsorption Column", THERAPEUTIC APHERESIS AND DIALYSIS, vol. 12, no. 6, 1 December 2008 (2008-12-01), pages 491 - 499, XP055001372, ISSN: 1744-9979, DOI: 10.1111/j.1744-9987.2008.00640.x *
ROBBERT G VAN DER MOST ET AL: "Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 58, no. 8, 4 December 2008 (2008-12-04), pages 1219 - 1228, XP019706344, ISSN: 1432-0851 *

Also Published As

Publication number Publication date
WO2013179143A2 (en) 2013-12-05

Similar Documents

Publication Publication Date Title
WO2013179143A3 (en) Sensitization of cancer cells by the removal of soluble tumor necrosis factor receptors
IL279330A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2012145183A3 (en) Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
HK1208151A1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer 182
AU2013216320A8 (en) C10RF32 Antibodies, And Uses Thereof For Treatment Of Cancer
EP3473651A3 (en) Tumor cell-derived microvesicles
IL238942A0 (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
WO2014011220A3 (en) A method of treating androgen receptor (ar)-positive breast cancers with selective androgen receptor modulator (sarms)
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
WO2012078688A3 (en) Humanized antibodies to liv-1 and use of same to treat cancer
SG10201704992SA (en) Lsr antibodies, and uses thereof for treatment of cancer
PT2766040T (en) Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early-stage breast cancer
WO2014153056A3 (en) Cancer treatment using antibodies that bing cell surface grp78
CL2014001282A1 (en) Use of an immunoconjugate of an antibody directed against the epidermal growth factor receptor (egfr) for the treatment of cancer resistant to the treatment directed against egfr, where the immunoconjugate is an antibody bound to a cytotoxic agent.
WO2012064834A3 (en) Methods for organ regeneration
NZ704719A (en) Cd133 aptamers for detection of cancer stem cells
IL222198A (en) Humanized anti cxcr4 antibodies for the treatment of cancer
WO2012138789A3 (en) Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
WO2009090651A3 (en) Major histocompatibility complex hla-b2705 ligands useful for therapy and diagnosis
SG10201903658QA (en) Personalized anti-cancer agent screening system
MX345467B (en) Method for inhibition of deubiquitinating activity.
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
EP2669363A4 (en) Dual body circulatory reactor for cellulose enzymolysis and application thereof
SI2852408T1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2015023776A3 (en) Deoxycytidine kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13758979

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13758979

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13758979

Country of ref document: EP

Kind code of ref document: A2